-

Allurion Announces Premium Tiers for the Virtual Care Suite and Launch of Proprietary “My Daily Action” Bundle

  • Company augments digital behavior change program with the launch of proprietary “My Daily Action” bundle
  • The Virtual Care Suite (VCS) – Allurion’s AI-powered remote patient monitoring and behavior change platform – is now available for license in three different tiers: one basic package and two premium plans
  • My Daily Action bundle will be available on the premium VCS+ and VCS Custom tiers
  • The tailored, evidence-based bundle empowers patients to try new practical actions, leading to new habits that can cement their chances of reaching – and maintaining – a healthier weight

NATICK, Mass.--(BUSINESS WIRE)--Allurion, a company dedicated to ending obesity, announced today the launch of premium tiers for the Virtual Care Suite and the launch of its proprietary “My Daily Action” bundle. The bundle is available in 15 languages and includes a library of evidence-based weight-loss actions related to mindset and habits, movement, wellbeing, and nutrition and eating.

Backed by cutting-edge behavioral science, My Daily Actions empowers patients to explore strategies that support healthy habit formation, which is essential for sustained weight loss and wellbeing. By self-selecting a simple action to accomplish, repeating the action daily, and tracking compliance through the Allurion App, patients develop new, healthier long-term habits. All the recommended actions are evidence-based, proven to support weight loss, improve wellbeing, and lead to a healthier lifestyle.

My Daily Actions has been developed and evaluated in a prospective study by Allurion’s Behavioral Science team, led by Dr. Paul Sacher, Allurion’s VP of Behavioral Science. The study incorporated proprietary weight-loss actions spanning mindset and habits, movement, wellbeing, and nutrition and eating. The study revealed that participants found the behavior change program beneficial and, as a result, implemented new, healthier actions into their daily routines to aid weight loss. Preliminary results of the study will be presented at the upcoming Canadian Obesity Summit on May 15, 2023.

“The goal of My Daily Actions is to help patients make permanent changes in their behaviors so that they can achieve long-lasting weight-loss success,” said Dr. Sacher. “We specifically designed this new Allurion App bundle using cutting-edge behavioral science to enhance the support offered to patients via the Virtual Care Suite. It is a proprietary, patient-centered feature that demonstrates Allurion’s laser focus on optimizing patient success.”

Unlike other cookie-cutter approaches, the My Daily Actions experience offers strategies that are tailored to the unique needs and challenges of each person. In addition, clinics can view a patient’s compliance with their actions to help track progress and support the patient to create healthier lifestyle habits.

The feature further enhances Allurion’s reputation as a world leader in science-led digital weight-loss services. Shantanu Gaur, M.D., Allurion’s Founder and Chief Executive Officer, said the My Daily Actions program was yet another robust tool to help weight-loss clinics enhance their care.

“Long-term weight loss is achieved through behavior change. Balloon, surgery, and drug therapy all need to be coupled with behavior change to cement lifelong healthy habits and long-term success. We developed My Daily Actions through years of research to create a first of its kind program for all patients using the Virtual Care Suite.”

Allurion offers flexibility to providers, who can choose between three different tiers of the Virtual Care Suite: one basic package and two premium plans. My Daily Actions is now available for providers using the premium VCS+ or VCS Custom plans. For providers who are interested in getting started with an AI-based remote patient monitoring solution, Allurion is now also offering a base VCS tier of services at no cost. This tier provides a wide range of features, with no charges for the software license for as many patients as desired. This pricing is not time-limited and is available today for anyone providing weight-loss care. Providers can upgrade to the premium packages at any time to take advantage of My Daily Actions.

About Allurion

Allurion is dedicated to ending obesity. The Allurion Program is a weight-loss platform that combines the Allurion Gastric Balloon, the world’s first and only swallowable, procedure-less gastric balloon for weight loss, the Allurion Virtual Care Suite, including the Allurion Mobile App for consumers, Allurion Insights for healthcare providers featuring the Iris AI Platform, and the Allurion Connected Scale and Health Tracker devices. The Allurion Virtual Care Suite is also available to providers separately from the Allurion Program to help customize, monitor and manage weight-loss therapy for patients regardless of their treatment plan: gastric balloon, surgical, medical or nutritional.

For more information about Allurion and the Allurion Virtual Care Suite, please visit www.allurion.com.

Allurion is a trademark of Allurion Technologies, Inc. in the United States and countries around the world.

Contacts

Media
Cedric Damour
PR Manager
+33 7 84 21 02 20
cdamour@allurion.com

Allurion Technologies, Inc.


Release Versions

Contacts

Media
Cedric Damour
PR Manager
+33 7 84 21 02 20
cdamour@allurion.com

Social Media Profiles
More News From Allurion Technologies, Inc.

Allurion Announces Initial Results on the Combination of the Allurion Program With Low-dose GLP-1 Therapy to Optimize Muscle Mass and GLP-1 Adherence

NATICK, Mass.--(BUSINESS WIRE)--Allurion Technologies, Inc. (“Allurion” or the “Company”) (NYSE: ALUR), a company dedicated to ending obesity, today announced initial results on the combination of the Allurion Program with low-dose GLP-1 therapy to optimize muscle mass and GLP-1 adherence. 52 patients treated with the Allurion Balloon were started on 0.25mg semaglutide after completing their first month of balloon therapy. The dose of semaglutide was increased to no greater than 1.0mg over the...

Allurion to Report Fourth Quarter 2024 Financial Results on March 26, 2025

NATICK, Mass.--(BUSINESS WIRE)--Allurion Technologies, Inc. (“Allurion” or the “Company”) (NYSE: ALUR), a company dedicated to ending obesity, today announced that it will report financial results for the fourth quarter 2024 on Wednesday, March 26, 2025. Company management will host a conference call to discuss financial results and provide a business update on the same day at 8:30 AM ET. To access the conference call by telephone, please dial (888) 330-3417 (domestic) or +1 646 960 0804 (inter...

Allurion Announces Notification of Issuance of New U.S. Patents on Next-Generation Weight Loss Device for the Treatment of Obesity

NATICK, Mass.--(BUSINESS WIRE)--Allurion Technologies, Inc. (“Allurion” or the “Company”) (NYSE: ALUR), a company dedicated to ending obesity, today announced that it has received two Issue Notifications from the U.S. Patent and Trademark Office (USPTO) dated February 19, 2025 for U.S. Patent No. 12,246,163 titled “Automatic-Sealing Balloon-Filling Catheter System” and U.S. Patent No. 12,245,962 titled “Balloon Sealing and Fill Valve”. These patents, both of which are scheduled to issue on Marc...
Back to Newsroom